| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Control of the Acute-Phase ResponseInstitut Pasteur de Lille (R.M,M., E.B., B.S., P.G.), Département d'Athérosclérose, and Institut National de la Santé et de la Recherche Médicale Unité 545, Lille F59019, France; and Faculté des Sciences Pharmaceutiques et Biologiques (R.M.M., B.S., P.G.), Université de Lille 2, Lille F-59006, France
Address all correspondence and requests for reprints to: Philippe Gervois, Laboratoire de biochimie, Faculté des Sciences Pharmaceutiques et Biologiques, 3, rue du professeur Laguesse, BP83, Lille F-59006, France. E-mail: philippe.gervois{at}univ-lille2.fr.
The acute-phase response is characterized by the modulation of liver expression of many proteins involved in a diversity of biological functions. Among them, some are associated with the pathology of atherosclerosis. We previously found that peroxisome proliferator-activated receptor-
(PPAR
) agonists attenuate the IL-6 induction of acute-phase response gene expression in vitro and in vivo. In the current work, we found a PPAR
-dependent regulation of hepatic acute-phase response stimulated by IL-1. We also found that IL-1-stimulated expression of secondary wave cytokines such as IL-6 is prevented upon PPAR
activation in liver. Direct involvement of hepatic PPAR
was demonstrated using a liver-restricted expression of PPAR
in mice. IL-1- or IL-6-mediated acute-phase response was inhibited by fenofibrate treatment in liver-specific PPAR
-expressing mice but not in PPAR
-deficient mice. In addition, we demonstrated that PPAR
exerts a general control of the acute-phase response by using an inflammation/infection model of lipopolysaccharide. In such a context, liver-specific PPAR
-expressing mice displayed lower circulating levels of TNF, IL-1, and IL-6 cytokines. We found a distal repercussion of this lowering at the vascular wall level as illustrated by a decreased expression of adhesion molecules in aorta. In conclusion, we demonstrated that through a specific liver action, PPAR
behaves as a modulator of systemic inflammation and of the associated vascular response.
This article has been cited by other articles:
![]() |
L. Makowski, R. C. Noland, T. R. Koves, W. Xing, O. R. Ilkayeva, M. J. Muehlbauer, R. D. Stevens, and D. M. Muoio Metabolic profiling of PPAR{alpha}-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation FASEB J, February 1, 2009; 23(2): 586 - 604. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |